Protalex, Inc. to Continue Phase 1b Trial of PRTX-100 in Patients With Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review

Published: Mar 07, 2013

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Data Safety Monitoring Committee, the Company is continuing enrollment and dosing of patients in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate and leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-100 for patients in the current treatment group (6.0 micrograms/kg) is four times that of the initial starting dosage (1.5 micrograms/kg).

Back to news